Healing Human Moderate and Large Traumatic Tympanic Membrane Perforations Using Basic Fibroblast Growth Factor, 0.3% Ofloxacin Eardrops, and Gelfoam Patching
The goal of this study was to evaluate the effects of basic fibroblast growth factor (bFGF), 0.3% ofloxacin eardrops (OFLX), and Gelfoam patching on the healing of human moderate and large traumatic tympanic membrane perforations (TMPs). A prospective, quasi-randomized, controlled clinical study. A...
Saved in:
Published in | Otology & neurotology Vol. 37; no. 6; p. 735 |
---|---|
Main Authors | , , , |
Format | Journal Article |
Language | English |
Published |
United States
01.07.2016
|
Subjects | |
Online Access | Get more information |
Cover
Loading…
Abstract | The goal of this study was to evaluate the effects of basic fibroblast growth factor (bFGF), 0.3% ofloxacin eardrops (OFLX), and Gelfoam patching on the healing of human moderate and large traumatic tympanic membrane perforations (TMPs).
A prospective, quasi-randomized, controlled clinical study.
A University-affiliated teaching hospital.
We performed a quasi-randomized prospective analysis between January 2010 and December 2014. All patients had traumatic TMPs covering areas >25% of the entire tympanic membrane. The closure rates, closure times, hearing gains, and rates of otorrhea in patients who underwent conservative observation, Gelfoam patching, topical bFGF application, and direct application of OFLX were compared.
We ultimately included 185 patients. Closure rates did not significantly differ among the four groups (p = 0.257). Post-hoc multiple comparisons also showed that the closure rates did not differ between any two groups (p > 0.083). The mean closure times were 25.6 ± 13.32, 12.3 ± 8.15, 14.3 ± 5.44, and 13.97 ± 8.82 days for the observation, bFGF, Gelfoam patch, and OFLX groups, respectively. The closure times of the four groups differed significantly (p < 0.001). Post-hoc multiple comparisons showed that the differences between the observation group and each of the other groups were significant (p < 0.001). No other between- or among-group differences were significant (p > 0.0083).
The findings of this study suggest that OFLX, bFGF, and Gelfoam patching accelerated the closure of human moderate and large traumatic TMPs. Hence, treatment of human traumatic TMPs should be revisited clinically. Topical application of OFLX may be recommended, because OFLX is more easily available and convenient than bFGF or Gelfoam patch for otology outpatients. |
---|---|
AbstractList | The goal of this study was to evaluate the effects of basic fibroblast growth factor (bFGF), 0.3% ofloxacin eardrops (OFLX), and Gelfoam patching on the healing of human moderate and large traumatic tympanic membrane perforations (TMPs).
A prospective, quasi-randomized, controlled clinical study.
A University-affiliated teaching hospital.
We performed a quasi-randomized prospective analysis between January 2010 and December 2014. All patients had traumatic TMPs covering areas >25% of the entire tympanic membrane. The closure rates, closure times, hearing gains, and rates of otorrhea in patients who underwent conservative observation, Gelfoam patching, topical bFGF application, and direct application of OFLX were compared.
We ultimately included 185 patients. Closure rates did not significantly differ among the four groups (p = 0.257). Post-hoc multiple comparisons also showed that the closure rates did not differ between any two groups (p > 0.083). The mean closure times were 25.6 ± 13.32, 12.3 ± 8.15, 14.3 ± 5.44, and 13.97 ± 8.82 days for the observation, bFGF, Gelfoam patch, and OFLX groups, respectively. The closure times of the four groups differed significantly (p < 0.001). Post-hoc multiple comparisons showed that the differences between the observation group and each of the other groups were significant (p < 0.001). No other between- or among-group differences were significant (p > 0.0083).
The findings of this study suggest that OFLX, bFGF, and Gelfoam patching accelerated the closure of human moderate and large traumatic TMPs. Hence, treatment of human traumatic TMPs should be revisited clinically. Topical application of OFLX may be recommended, because OFLX is more easily available and convenient than bFGF or Gelfoam patch for otology outpatients. |
Author | Lou, Zheng-Cai Liu, Ya-Chao Lou, Zi-Han Chang, Jiang |
Author_xml | – sequence: 1 givenname: Zheng-Cai surname: Lou fullname: Lou, Zheng-Cai organization: Department of Otorhinolaryngology, Affiliated YiWu Hospital of Wenzhou Medical University, Yiwu City, China †Department of Clinical Medicine, No.11, Xinxiang Medical University, Xinxiang City, China ‡Department of Otolaryngology Head and Neck Surgery, No.1, Affiliated Hospital of Hebei North University, Zhangjiakou City, China §Department of Pediatric Otolaryngology, Children's Hospital of Dongguan, Dongguan City, China – sequence: 2 givenname: Zi-Han surname: Lou fullname: Lou, Zi-Han – sequence: 3 givenname: Ya-Chao surname: Liu fullname: Liu, Ya-Chao – sequence: 4 givenname: Jiang surname: Chang fullname: Chang, Jiang |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/27295381$$D View this record in MEDLINE/PubMed |
BookMark | eNpNkMtOwzAQRS0Eog_4A4S8YdcUO47tZFkq2iK1ahftuhondhuU2JGdCvox_CvhJTGbO5q594w0A3RpndUI3VEypiSTj6vJekz-FSUpuUB9ypmMEk54Dw1CeO3mknF5jXqxjDPOUtpHHwsNVWkPeHGqweKVK7SHVmOwBV6CP2i89dCt2jLH23PdgO2ala6VB6vxRnvjOn_pbMC78MV5gtA5ZqXyTlUQWjz37q094hnkrfMjTMbsAa9N5d4hLy1-Bl9414TR98W5royDGm-gzY8d7QZdGaiCvv3VIdrNnrfTRbRcz1-mk2WUMx6TiBrDkliYxAgdC8E1UYIqrmSmCpECKYQSRuo8z2TMGAcgOUhGk5QmsZRddIjuf7jNSdW62De-rMGf939_ij8BH3proA |
CitedBy_id | crossref_primary_10_1016_j_amjoto_2020_102405 crossref_primary_10_1097_MAO_0000000000001264 crossref_primary_10_1186_s40463_020_00440_7 crossref_primary_10_1002_lary_28914 crossref_primary_10_1016_j_bjorl_2020_03_007 crossref_primary_10_1097_MAO_0000000000001265 crossref_primary_10_1177_0194599818757972 crossref_primary_10_1016_j_amjoto_2020_102399 crossref_primary_10_1016_j_amjoto_2019_02_015 crossref_primary_10_1016_j_cej_2021_129536 crossref_primary_10_1155_2021_5583046 crossref_primary_10_3390_pharmaceutics12060508 crossref_primary_10_1089_ten_tea_2016_0265 crossref_primary_10_1177_01455613241264479 crossref_primary_10_1155_2021_2366291 crossref_primary_10_3389_fnmol_2021_757441 crossref_primary_10_1017_S0022215117001001 crossref_primary_10_1017_S002221511800083X crossref_primary_10_1097_MAO_0000000000002628 crossref_primary_10_1016_j_amjoto_2022_103650 crossref_primary_10_1007_s00405_021_06891_6 crossref_primary_10_1089_ten_teb_2020_0176 crossref_primary_10_1097_MAO_0000000000002036 crossref_primary_10_12677_acm_2024_143885 |
ContentType | Journal Article |
DBID | CGR CUY CVF ECM EIF NPM |
DOI | 10.1097/MAO.0000000000001080 |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) |
DatabaseTitleList | MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | no_fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1537-4505 |
ExternalDocumentID | 27295381 |
Genre | Randomized Controlled Trial Research Support, Non-U.S. Gov't Journal Article |
GroupedDBID | --- .-D .GJ .Z2 0R~ 123 1J1 4Q1 4Q2 4Q3 53G 5VS AAAAV AAHPQ AAIQE AAMTA AARTV AASCR AASOK AAWTL AAYEP ABASU ABBUW ABDIG ABJNI ABVCZ ABXVJ ABZAD ABZZY ACBNA ACCJW ACDDN ACEWG ACGFS ACILI ACNWC ACWDW ACWRI ACXJB ACXNZ ADFPA ADGGA ADHPY ADNKB AE3 AE6 AEETU AENEX AFBFQ AFDTB AFUWQ AGINI AHQNM AHRYX AHVBC AINUH AJCLO AJIOK AJNWD AJNYG AJZMW AKCTQ ALKUP ALMA_UNASSIGNED_HOLDINGS ALMTX AMJPA AMKUR AMNEI AOHHW AOQMC BQLVK BS7 C45 CGR CUY CVF DIWNM DU5 DUNZO E.X EBS ECM EEVPB EIF EJD EX3 F2K F2L F2M F2N FCALG FL- FW0 GNXGY GQDEL H0~ HLJTE HZ~ IKREB IN~ IPNFZ JF9 JG8 JK3 JK8 K8S KD2 KMI L-C L7B N4W N9A NPM N~M O9- OAG OAH OCUKA ODA OHT OL1 OLV OLZ OPUJH ORVUJ OUVQU OVD OVDNE OWU OWV OWX OWY OWZ OXXIT R58 RIG RLZ S4R S4S T8P TEORI TSPGW V2I VVN W3M WOQ WOW X3V X3W XXN XYM ZFV ZGI ZZMQN |
ID | FETCH-LOGICAL-c3520-1ff3426f4f6e2665e0b61b5b79bd68a0d6b6f7ecc972335aa0ca7314814277342 |
IngestDate | Thu Apr 03 07:01:19 EDT 2025 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 6 |
Language | English |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c3520-1ff3426f4f6e2665e0b61b5b79bd68a0d6b6f7ecc972335aa0ca7314814277342 |
PMID | 27295381 |
ParticipantIDs | pubmed_primary_27295381 |
PublicationCentury | 2000 |
PublicationDate | 2016-07-00 |
PublicationDateYYYYMMDD | 2016-07-01 |
PublicationDate_xml | – month: 07 year: 2016 text: 2016-07-00 |
PublicationDecade | 2010 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States |
PublicationTitle | Otology & neurotology |
PublicationTitleAlternate | Otol Neurotol |
PublicationYear | 2016 |
References | 27755460 - Otol Neurotol. 2016 Dec;37(10 ):1680 27755459 - Otol Neurotol. 2016 Dec;37(10 ):1679-1680 |
References_xml | – reference: 27755459 - Otol Neurotol. 2016 Dec;37(10 ):1679-1680 – reference: 27755460 - Otol Neurotol. 2016 Dec;37(10 ):1680 |
SSID | ssj0017357 |
Score | 2.2765598 |
Snippet | The goal of this study was to evaluate the effects of basic fibroblast growth factor (bFGF), 0.3% ofloxacin eardrops (OFLX), and Gelfoam patching on the... |
SourceID | pubmed |
SourceType | Index Database |
StartPage | 735 |
SubjectTerms | Adult Anti-Bacterial Agents - therapeutic use Female Fibroblast Growth Factor 2 - therapeutic use Gelatin Sponge, Absorbable - therapeutic use Humans Male Middle Aged Ofloxacin - therapeutic use Prospective Studies Treatment Outcome Tympanic Membrane - drug effects Tympanic Membrane Perforation - drug therapy Wound Healing - drug effects Young Adult |
Title | Healing Human Moderate and Large Traumatic Tympanic Membrane Perforations Using Basic Fibroblast Growth Factor, 0.3% Ofloxacin Eardrops, and Gelfoam Patching |
URI | https://www.ncbi.nlm.nih.gov/pubmed/27295381 |
Volume | 37 |
hasFullText | |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnZ1bb9MwFMetbkiIFzTujIv8AE9ZIPe0j6NaqdBKeeik8TTZib1WWpMJpRrwXfZt9sH4H9vpQhni0ococtokyvnVOcc-52_GXiUqyQd9gdgkkqWfqCz0he5LX8PWcdlPZRJTofDkYzY-Sj4cp8e93lUna2nVyDfF9xvrSv7HqmiDXalK9h8suz4pGrAP-2ILC2P7VzamGiIK9e1IvFnWDK6jmQ84pAxvki5fWU3W2Tf632NnopYIkOFafjKJ7S4TzmYOvBOwmTdCBF1LeNUNjUxdNHNvJOzQ_tBD9P06Sr2pPqu_imJReQcg7EttZxPouu_Vma7FkqT_TZZm1_mdNlbwiWgzOprNT2P6h_XKTJXMVXXqD8Vis33hjzsJRAvT-Fn4w7moO0kKLsMY1J92RzTCbJ39ihdS2wuTGHuQdrtpqw3jcOz2ubnVO_nlXWA1hif7U6tR6T6UU9n9Oix6vjR8RIgz0P2Hfz66odDdHtpiW4hVaPFVGjFyM1m4u7wt2Rzkb2-6HRKkdqfYCG6MkzPbYXdddML3LWr3WE9V99nticu_eMAuHXHcEMdb4jgszw1xfE0cb4njLXG8Sxw3xHFDHL8mjlviuCVujxNvfE0bb2nbM1d0rPGWtYfsaHQwG459t8CHX8DvD_xQ6xgeok50puAopiqQWShTmQ9kmfVFUGYy0zk6GVoaL06FCAqRxwjgwyTKc_z0Eduu6ko9IekBWkYbDmcB_5iqy1WaqCjSMs50GZTqKXtsH-zJuVVxOWkf-e5vjzxjd67xfM5uaXQb6gV80Ea-NEb-AUYzhBo |
linkProvider | National Library of Medicine |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Healing+Human+Moderate+and+Large+Traumatic+Tympanic+Membrane+Perforations+Using+Basic+Fibroblast+Growth+Factor%2C+0.3%25+Ofloxacin+Eardrops%2C+and+Gelfoam+Patching&rft.jtitle=Otology+%26+neurotology&rft.au=Lou%2C+Zheng-Cai&rft.au=Lou%2C+Zi-Han&rft.au=Liu%2C+Ya-Chao&rft.au=Chang%2C+Jiang&rft.date=2016-07-01&rft.eissn=1537-4505&rft.volume=37&rft.issue=6&rft.spage=735&rft_id=info:doi/10.1097%2FMAO.0000000000001080&rft_id=info%3Apmid%2F27295381&rft_id=info%3Apmid%2F27295381&rft.externalDocID=27295381 |